Ondansetron 4 Mg/2 Ml Fresenius, Ondansetron 8 Mg/4 Ml Fresenius 4 mg/2 ml, 8 mg/4 ml Solution for injection or infusion
PDF Leaflet Revision Date: 08 June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Management of nausea and vomiting induced by chemotherapy, radiotherapy, and post-operative nausea and vomiting.
Dosage (summary)
Adults: 8 mg IV/IM before treatment; max 16 mg for highly emetogenic chemotherapy. Elderly: max 8 mg IV for patients u226575 years.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in the first 12 weeks of pregnancy and for PONV during pregnancy; avoid breastfeeding.
Key Drug Interactions
- QT prolonging medicines
- Serotonergic medicines
- Apomorphine
Contraindications
- Hypersensitivity to ondansetron
- Congenital long QT syndrome
Common side effects
- Headache
- Constipation
- Dizziness
- Visual disturbances
Counselling Points
- Avoid driving if experiencing dizziness
- Report any signs of allergic reactions
- Monitor for signs of QT prolongation
Serious warnings
- QT prolongation
- Risk of myocardial ischaemia
- Serotonin syndrome
Important Disclaimer
The Ondansetron 4 Mg/2 Ml Fresenius, Ondansetron 8 Mg/4 Ml Fresenius 4 mg/2 ml, 8 mg/4 ml Solution for injection or infusion professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
